The content on this site is intended for healthcare professionals only
Prof Dirk Schadendorf talks to ecancer at ECC 2013 about a meta-analysis of a collection of trials investigating ipilimumab.
By pooling all of the 1,800 patients analysed for long term survival, in addition to more than 2,000 patients in early access programmes, researchers were better able to understand the overall durability of the drug in melanoma.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Optimizing oncology: The future of treatment studies
Advancements in head and neck cancer treatment in India
Advancements in paediatric Acute lymphoblastic leukemia management
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
